Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY ... below the mean price target of $988.61. The Street-high price target of $1,190 implies a modest ...

Eli Lilly's (LLY) fourth quarter and full-year earnings mostly met Wall Street estimates but missed expectations for sales of its weight loss GLP-1 drugs Mounjaro and Zepbound.

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Wall Street was poised for a flat start as investors analyzed earnings from major companies like Honeywell and anticipated ...